Dartmouth-led team engineers new treatment for drug-resistant bacterial infections

(Thayer School of Engineering at Dartmouth) A new antibacterial agent that has been engineered by researchers at Dartmouth to essentially hide from the human immune system may treat life-threatening MRSA infections. A new paper, published today in Science Advances, provides details on the agent, which is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections.